<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The treatment with APNO reduced the serum cholesterol levels of the rats in the HFD + APNO group similar to the reduction in the HFD + S (simvastatin) and HFD + C (ciprofibrate) groups, as compared to the HFD group (
 <xref rid="molecules-23-00960-t004" ref-type="table" class="xref">Table 4</xref>). Statins and fibrates are drugs used clinically to reduce the serum cholesterol lipids and triglycerides in humans [
 <xref rid="B37-molecules-23-00960" ref-type="bibr" class="xref">37</xref>,
 <xref rid="B38-molecules-23-00960" ref-type="bibr" class="xref">38</xref>]. Statins inhibit HMG-CoA reductase, which promotes the reduction of cholesterol synthesis in liver cells, whereas the fibrates act as PPAR-Î± agonists that lead to the further degradation and excretion of lipids [
 <xref rid="B38-molecules-23-00960" ref-type="bibr" class="xref">38</xref>].
</p>
